Citations

Clear

7732 citation(s) found for "Ma, Daniel".

Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome
Montes, Daniel, Langenfeld, Hannah E., Hanson, Andrew C., Crowson, Cynthia S. , Patnaik, Mrinal M., Go, Ronald S. , Kalantari, Kambiz , Kusne, Yael, Lasho, Terra, Mangaonkar, Abhishek A. , Olteanu, Horatiu , Reichard, Kaaren K., Sullivan, Megan M. , Viswanatha, David S., Warrington, Kenneth J. , Koster, Matthew J.

Mayo Clinic

ACR Open Rheumatology | September 24, 2026 | Volume: 8 | Issue: 10 | Pages: No page available

10.1002/acr2.90153 | PMID 42782167 Get It

Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors (TNFαi), or interleukin‐1 (IL‐1) or IL‐6 inhibitors were identified. Clinical and biochemical data were recorded for patients at time of targeted therapy initiation, and at 3‐, 6‐, and 12‐month follow‐up time points. Treatment response was labeled as complete response (CR; normalization of C‐reactive protein [CRP], prednisone <10 mg/day, and resolution of disease activity), partial response (PR; >50% improvement in CRP, >50% prednisone dose reduction, improvement or resolution of disease features), treatment failure (TF; worsening CRP, increasing prednisone, worsening of disease features), or no response (not meeting criteria for CR, PR, or TF). Results Overall, 52 patients received an IL‐1i, IL‐6i, or JAKi therapy. At six‐month follow‐up, 3 of 19 IL‐6i patients experienced CR, 4 of 19 experienced PR, and 7 of 19 experienced TF. 2 of 17 patients receiving JAKi experienced CR, 3 of 17 experienced PR, and 6 of 17 experienced TF. No patients receiving IL‐1i or TNFαi experienced CR, and only 1 of 5 IL‐1i patients experienced PR. Among those still receiving biologic therapy at 12 months, only 1 of 11 receiving IL‐6i and 0 of 7 receiving JAKi experienced CR. Conclusion IL‐6i and JAKi therapies demonstrated limited, unsustained efficacy for management of VEXAS syndrome. IL‐1i and TNFαi therapies were not efficacious. Useful application of previously reported treatment response criteria was demonstrated, but future incorporation of hematologic parameters may be beneficial.
ASOFormer: a Transformer-based model for predicting antisense oligonucleotide efficacy to support therapeutic candidate prioritization
Dove, Nicholas C. , Min, Yuhao , İş, Özkan , Ertekin, Nilüfer , Wickland, Daniel P. , Wang, Xue

Mayo Clinic

No container title available | September 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.18.752788 Get It

Antisense oligonucleotides (ASOs) represent a promising therapeutic modality for RNA-based disease mechanisms, but identifying high-efficacy candidates from large sequence spaces remains a major bottleneck in drug development. Here, we present ASOFormer, a novel Transformer-based neural network that predicts the inhibition efficiency of RNase H-mediated ASOs from sequence, predicted secondary structure, and chemical modification features. ASOFormer was trained on a knockdown efficacy dataset spanning over 170,000 ASO-target pairs compiled largely from published patents. Ablation analysis confirmed that the addition of chemical modification features to the primary sequence drove the largest performance gains, with predicted secondary structure providing complementary benefit when combined with modification information. Further analysis highlighted the importance of the wings of gapmer ASOs and other features. As independent validation, ASOFormer was applied to ASOs targeting seven genes that were not in the training dataset gene list. For four out of the seven genes, the ground truth ASO inhibition efficiency was obtained from a public dataset, whereas the others were measured in-house via qPCR. Compared to two published state-of-the-art methods, ASOFormer achieved the best overall accuracy and prioritized the strongest inhibitors. Crucially, only ASOFormer consistently exceeded random expectation for top-candidate recovery across all seven test genes.
Projected Cancer Burden among Sexual and Gender Minorities by Generation in the United States
Xu, Crystal W. , Mani, Kyle , Dickstein, Daniel R. , Patel, Rohan K. , Wang, Ming , Xu, Yifei , Zaorsky, Nicholas G. , Wang, Ming , Dickstein, Daniel R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF9

10.1158/1055-9965.epi-26-0504 | PMID 42770946 Get It

Abstract Background: Sexual and gender minority (SGM) representation is growing in the United States. This study estimated the future SGM cancer burden amidst shifting cancer patterns. Methods: Age-specific incidence data for breast, prostate, colorectal, lung, and melanoma were obtained from the Surveillance, Epidemiology, and End Results Program’s 12-registry database. Nordpred age-period-cohort models projected incidence through 2040 to 2044. Rates were applied to US Census population estimates and generation- and sex-specific SGM identification proportions from Gallup’s 2023 to 2024 surveys. Prophet was used for sensitivity analysis. Results: At ages 55 to 59, breast cancer cases among Millennial SGMs were 3,672% higher than among Silent Generation SGMs (34,850 vs. 924 cases), melanoma cases were 1,061% higher (5,526 vs. 476 cases), and colorectal cancer cases were 2,206% higher (23,594 vs. 1,023 cases). Compared with Generation X, Millennial prostate cancer cases were 142% higher (8,100 vs. 3,344 cases), and lung cancer cases were 169% higher (5,451 vs. 2,029 cases). By 2040 to 2044, Millennials were projected to account for 68.4% of breast cancer cases and 59.7% of colorectal cancer cases among SGMs. Conclusions: At ages 55 to 59, the 5-year cancer burden was projected to be 15 times higher among Millennials than Silent Generation SGMs (77,521 vs. 5,134 cases), driven primarily by the larger SGM population in younger generations. Oncology systems will need to prepare for the increase in cancer care demand. Impact: These findings identify a substantial generational shift in the SGM cancer burden and may inform oncology workforce capacity, culturally responsive cancer care, and healthcare system preparation for this growing population.
Sotatercept Improves Right Heart Mechanics Despite Reduced Myocardial Contractility in Pulmonary Arterial Hypertension: A Prospective Exercise Hemodynamic Study
Reddy, Yogesh N.V. , Kazui, Sho , Miranda, William R. , Harada, Tomonari , Frantz, Robert P. , Burkhoff, Daniel , Borlaug, Barry A. , Borlaug, Barry A , Frantz, Robert P , Burkhoff, Daniel , Kazui, Sho

Mayo Clinic

Circulation | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circulationaha.126.081334 | PMID 42770225 Get It

BACKGROUND: The right ventricular (RV) response to pressure overload is a crucial determinant of outcomes in pulmonary arterial (PA) hypertension. Sotatercept improves clinical outcomes, but its effects on the right ventricle have been inconsistent. We evaluated the effects of sotatercept on load-independent measures of RV contractility, RV–PA coupling, and right heart deformation at rest and exertion in patients with PA hypertension. METHODS: In this prospective trial among participants with PA hypertension recruited between July 2024 and May 2025, we performed simultaneous echocardiography and invasive pressure measurements during rest and exercise to evaluate changes in RV contractility (end-systolic elastance [Ees]), afterload (PA elastance [Ea]), RV–PA coupling (ratio of arterial Ea to Ees), and right heart deformation, including RV and right atrial strain, before and after 24 weeks of sotatercept using mixed models. RESULTS: Among 30 participants (n=21; 70% female; mean age, 49.3 years [SD 13.5]), sotatercept decreased PA Ea. These changes were associated with reduced RV contractility, PA pulsatility index, and the maximal rate of RV pressure increase over time (dP/dt max ; P <0.001 for all). The decrease in Ees was associated with a decrease in PA Ea (r=+0.70 [95% CI, +0.44 to +0.85]; P <0.0001) with preserved RV–PA coupling (mean difference, +0.08 [95% CI, −0.11 to +0.26]; P =0.42). Although systolic indices measured at the base of the right ventricle (tricuspid annular plane systolic excursion and systolic velocity of the lateral tricuspid annulus) decreased after sotatercept use, there was an increase in RV free wall–dependent systolic indices, including resting and exercise RV free wall strain (mean difference, +6.2% [95% CI, +4.5 to +7.8]; P <0.0001) and fractional area change ( P =0.0001). Beyond the right ventricle, there was also improved right atrial filling and contractile performance across rest and exercise ( P <0.0001 for all). CONCLUSIONS: Sotatercept decreases RV contractility in proportion to reduced afterload, while preserving the RV–PA coupling relationship. Despite decreased RV contractility, global measures of right heart performance, such as RV free wall strain and RA strain, improve, alongside redistribution of RV deformation from annular motion to free wall shortening. These data suggest that sotatercept causes an energetically favorable reduction in resting RV contractility to match the lower afterload, which does not appear physiologically detrimental when considering the concurrent improvement in RV free wall contractile mechanics and exertional right heart reserve. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06409026.
Complications of ReActiv8 for chronic low back pain: an analysis of the FDA MAUDE database
Conic, Rosalynn R. Z., Kivanc, Tugba, Fischer, Azadeh, Pasya, Sai K., Palmer, Scott, Kubrova, Eva , Eldrige, Jason S. , Hurdle, Mark FB , Hunt, Christine L., Gupta, Sahil, Kanahan Osman, Sharima, Conic, Rosalynn R.Z. , Kivanc, Tugba Yavuz, Fischer, Azadeh, Pasya, Sai Kumar Reddy , Kanahan-Osman, Sharima , Wang, Daniel , Hunt, Christine L., Gupta, Sahil

Mayo Clinic

Pain Management | September 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.1080/17581869.2026.2736037 | PMID 42762487 Get It

Toxicity Attribution During Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Practical Framework
Zarka, Jabra, Childs, Daniel S. , Rincón, Miguel Muñiz, Tarhini, Ali , Jang, Albert , Kottschade, Lisa A. , Markovic, Svetomir N, Spychalla, Megan, Sitenga, Morgan, NGUYEN, GIANG, Pagliaro, Lance, Costello, Brian A, Orme, Jacob J., Zarka, Jabra G , Muniz Rincon, Miguel, Tarhini, Ali , Muniz, Miguel , Jang, Albert , Zarka, Jabra , Jang, Albert , Spychalla, Megan, Pagliaro, Lance C. , Costello, Brian A. , Orme, Jacob J.

Mayo Clinic

The Oncologist | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/oncolo/oyag371 | PMID 42768457 Get It

Abstract Enfortumab vedotin (EV), pembrolizumab, and EV plus pembrolizumab (EV/P) have rapidly reshaped the treatment landscape of advanced urothelial carcinoma, but toxicity increasingly determines treatment delivery, treatment continuity, and real-world benefit. As EV/P moves into broader clinical use, clinicians must distinguish adverse events related to antibody-drug conjugate exposure from immune-mediated toxicities and recognize syndromes in which both mechanisms may contribute. In this practical, mechanism-informed review, we synthesize pivotal trials, mature follow-up reports, and representative real-world cohorts describing the safety of EV monotherapy, pembrolizumab monotherapy, and EV/P in urothelial carcinoma. Because adverse-event reporting and ascertainment are heterogeneous across studies, including differences in preferred terms, composite categories, grading frameworks, and treatment-related versus all-cause reporting, we emphasize clinically interpretable patterns rather than pooled estimates. EV monotherapy is characterized by cutaneous toxicity, peripheral neuropathy, hyperglycemia, dysgeusia, and ocular events, including early epithelial/metabolic events and cumulative neuropathy. Pembrolizumab monotherapy has a lower overall high-grade toxicity burden but is defined by immune-mediated endocrinopathies, pneumonitis, hepatitis, colitis, and nephritis. Combination therapy produces a predictable overlap of these toxicity domains, creating diagnostic and management challenges for syndromes such as skin toxicity, diarrhea, fatigue, and pulmonary symptoms. We provide comparative visual toxicity signatures, regimen-specific summary tables, temporal toxicity mapping, and a pragmatic attribution framework that classifies events as EV-predominant, immune-predominant, overlap/indeterminate, or high-risk requiring initial interruption of both agents. This review aims to support bedside recognition, provisional attribution, early management, and safer implementation of EV/P in contemporary urothelial carcinoma practice.
Chemotherapy Versus Surgery for Stage IIA Nonseminomatous Germ Cell Tumor: A Comparative Cost Utility Analysis
Sharma, Vidit , Boorjian, Stephen A., Wymer, Kevin , Ratcliff, G., Penson, David F. , Leibovich, Bradley C., Costello, Brian A., Pagliaro, Lance C. , Barocas, Daniel A., Joyce, Daniel D., Boorjian, Stephen A. , Ratcliff, Grace E., Graves, John A. , Costello, Brian A. , Barocas, Daniel A.

Mayo Clinic

Journal of Urology | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ju.0000000000005317 | PMID 42758859 Get It

Risk Factors Associated with Positive Intraoperative Valve Tissue Cultures and the Subsequent Impact on Infective Endocarditis Management and Outcomes
Bhattarai, Nirjan , Stevens, Ryan W. , Baddour, Larry M. , DeSimone, Daniel C. , Chesdachai, Supavit , Hindy, Joya-Rita , Dierkhising, Ross , Ilges, Dan , Baddour, Larry , DeSimone, Daniel C , Stevens, Ryan W , Ilges, Dan , Dierkhising, Ross A

Mayo Clinic

Open Forum Infectious Diseases | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ofid/ofag568 | PMID 42824640 Get It

Abstract Background Cardiac valve tissue obtained during the surgical management of infective endocarditis (IE) and sent for culture may influence postoperative antibiotic therapy. We sought to identify clinical and microbiologic risk factors associated with positive valve cultures (PVC) and IE relapses in a cohort of patients undergoing surgical management. Methods This is a retrospective, multi-center study of patients with surgical management during the acute (&lt;42 days) course of IE-directed antibiotic therapy. The rate of PVC, IE relapse, and mortality were collected. Univariate and multivariable logistic regressions were performed to identify risk factors associated with PVC. Results Of 113 patients included, 36 (31.9%) had PVC. Univariate and multivariable analyses showed preoperative antibiotic duration and pathogens were associated with PVC. Median (IQR) days of preoperative antibiotics were 6.5 (4.0-11.0) for patients with PVC compared to 13.0 (8.0-21.0) for those with negative valve cultures (NVC). In a multivariable model, preoperative antibiotic administration decreased the risk of PVC (OR 0.85 per day, CI 0.77-0.91). Enterococcal IE increased the risk of PVC compared to streptococcal IE (OR 4.16, CI 1.07-17.48). Of note, 33 (63.2%) patients with NVC received a median (IQR) of 8 (5, 18.5) days of intravenous antibiotics per patient. Only one IE relapse was identified and occurred in a patient with NVC. Conclusions Both preoperative antibiotic duration and causative pathogen were associated with PVC. IE relapses were rare and unrelated to PVC. There may be an opportunity to shorten postoperative antibiotic durations following surgical management in patients with IE.
Scuba-related injuries presenting to United States emergency departments: paediatric and adult patterns
Tom, Andy, Lindberg, Sam, Navarro, Sergio, Stephens, Daniel , Navarro, Sergio M. , Stephens, Daniel

Mayo Clinic

Diving and Hyperbaric Medicine Journal | September 17, 2026 | Volume: 56 | Issue: 3 | Pages: 303-308

10.28920/dhm56.3.303-308 | PMID 42743570 Get It

Introduction: Scuba diving is a popular sport that carries risks unique to the underwater environment. Paediatric emergency department presentations for scuba diving injuries are incompletely characterised, particularly in comparison with adults. Methods: We retrospectively analysed scuba-related injuries recorded in the National Electronic Injury Surveillance System (NEISS) from 2005–2024. We estimated national paediatric emergency department presentations using NEISS weights and compared injury categories and hospitalisation rates between paediatric and adult patients. Results: We identified 68 paediatric cases, corresponding to an estimated 122 paediatric scuba-related emergency department presentations annually. Trauma was the most common injury category (41.2%), followed by otitis (17.6%) and ear, sinus, ocular, or dental barotrauma (16.2%). Hospitalisation was most common among patients with possible decompression sickness or arterial gas embolism (DCS/AGE) (42.9%) and drowning/aspiration (25.0%). Compared with adults, paediatric patients were less often hospitalised (10.3% vs 21.4%, P = 0.038), more likely to present with traumatic injuries (41.2% vs 26.1%, P = 0.010), and less likely to present with possible DCS/AGE (10.3% vs 25.0%, P = 0.006). Conclusions: Among patients presenting to United States emergency departments with scuba-related injuries, paediatric patients most commonly had trauma, otitis, or ear, sinus, ocular, or dental barotrauma. Paediatric divers were also less likely than adults to experience DCS/AGE injuries and were less likely than adults to require hospitalisation. Our data describes emergency department presentation patterns rather than overall injury risk among paediatric scuba divers.
Postmenopausal Status Is Associated With Increased Risk of Medial Meniscus Posterior Root Tears and Subsequent Arthroplasty
Panos, Joseph A. , Teubner, Lauren, Long, Kyndra , Tagliero, Adam , Nagelli, Christopher V , Krych, Aaron J , Teubner, Lauren , Tagliero, Adam J. , Hevesi, Mario , Saris, Daniël B.F. , Nagelli, Christopher V. , Krych, Aaron J.

Mayo Clinic

Arthroscopy | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/arj.70561 | PMID 42750098 Get It

Purpose To identify risk factors for medial meniscus posterior root tears (MMPRT) and arthroplasty‐free survival in postmenopausal women, while secondary objectives included analyzing menopause‐specific factors associated with MMPRT and defining risk factors for conversion to arthroplasty in patients with a confirmed MMPRT. Methods All patients at our institution with a diagnosed meniscal tear through December 2024 were identified. From this cohort, women with a menopausal diagnosis preceding their meniscal tear were matched one‐to‐one with men by age and body mass index. Imaging studies were reviewed to identify MMPRTs. Subsequent arthroplasty, Charlson Comorbidity Index, menopausal type (surgical or physiologic), hormone replacement therapy, bisphosphonate usage, and bone mineral density were recorded. Logistic and Cox regression were used to define risk factors for MMPRT and arthroplasty; survivorship was determined using Kaplan‐Meier analyses. Results The final cohort consisted of 1564 patients (n = 782 women) with a median age of 63 years, of which 244 patients (15.6%) had MMPRT. Age and female sex were associated with MMPRT. The presence of an MMPRT, female sex, body mass index, and Charlson Comorbidity Index were associated with arthroplasty. Among postmenopausal women, age at menopause, surgical menopause, hormone replacement therapy, and bone mineral density were associated with MMPRT. For patients with MMPRT, female sex was associated with arthroplasty. Ten‐year survivorship‐free from arthroplasty in patients with MMPRT was 53.5% for women and 78.4% for men ( P = .02). Conclusions Postmenopausal status, age, and hormone replacement therapy usage are risk factors for MMPRT. Compared with men, postmenopausal women with MMPRT exhibit reduced arthroplasty‐free survival, underscoring the need for targeted interventions. Level of Evidence Level III, retrospective comparative study.